We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
KOD Stock Up 24% in 3 Months: Here's What You Need to Know
Read MoreHide Full Article
Key Takeaways
Kodiak Sciences stock surges as late-stage programs for DR, wet AMD and macular edema drive momentum.
KOD's tarcocimab, KSI-501 and KSI-101 are in pivotal studies with multiple top-line readouts through 2027.
Kodiak Sciences bolstered its balance sheet via an 8.0M-share equity offering, extending its cash runway.
Kodiak Sciences’ (KOD - Free Report) shares have surged 24% over the past three months, driven by strong momentum around its late-stage pipeline and improving financial position, which have boosted investor confidence.
The company’s lead programs—tarcocimab, KSI-501 and especially KSI-101—are in late-stage development for common and serious retinal indications such as diabetic retinopathy (DR), wet age-related macular degeneration (wet AMD) and macular edema.
Over the past year, shares of Kodiak have surged 290.5% compared with the industry’s 34.9% growth.
Image Source: Zacks Investment Research
Kodiak’s Strong Pipeline a Catalyst
Investor sentiment has been bolstered by clear visibility on multiple late-stage catalysts. Building on the success of the GLOW1 study, Kodiak is evaluating the efficacy and safety of tarcocimab in treatment-naïve patients with DR in the phase III GLOW2 study, with top-line data expected in the first quarter of 2026.
KOD’s second clinical candidate, KSI-501, a dual inhibitor Trap-Antibody-Fusion bioconjugate molecule, is designed to target concurrent inflammation and abnormal angiogenesis observed in the pathogenesis of retinal vascular diseases.
The company is also studying tarcocimab as a second investigational arm in the phase III DAYBREAK study for the treatment of patients with wet AMD, with KSI-501 being the first investigational arm. Top-line data from both arms of the DAYBREAK study are anticipated in the third quarter of 2026.
Success in these pivotal programs could enable a single regulatory filing for tarcocimab across three major retinal indications, representing a significant commercial opportunity.
Kodiak has advanced KSI-101, its third clinical candidate, into two pivotal phase III studies (PEAK and PINNACLE) for the treatment of patients with macular edema secondary to inflammation (MESI). Both studies are currently enrolling patients with top-line results expected in late 2026 and early 2027, respectively.
Additionally, Kodiak is evaluating KSI-101 in the same patient population under an early-stage APEX study. In November, the follow-up data from the study demonstrated meaningful visual improvements and retinal drying, validating its dual IL-6 and VEGF mechanism. Final data from the study is expected to be released shortly.
Although Kodiak remains a clinical-stage biotech with no approved products, the steady progress of its potential pipeline candidates reinforced investor confidence, which underpinned the stock’s recent run.
Robust Funding
Kodiak Sciences completed a successful equity offering of 8.0 million shares in December 2025, which strengthened its balance sheet and extended the company’s cash runway to support operations and pipeline development.
Over the past 60 days, estimates for Assertio’s 2026 loss per share have narrowed from 30 cents to 28 cents. ASRT shares have declined 2% over the past year.
Assertio’s earnings beat estimates in one quarter and missed in the remaining three quarters, with the average negative surprise being 35.21%.
Over the past 60 days, estimates for Alkermes’ 2026 earnings per share have increased from $1.54 to $1.91. ALKS shares have risen 6.3% over the past year.
Alkermes’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average earnings surprise being 4.58%.
Over the past 60 days, estimates for Castle Biosciences’ 2026 loss per share have narrowed from $1.06 to 96 cents. CSTL shares have risen 17.3% over the past year.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 66.11%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
KOD Stock Up 24% in 3 Months: Here's What You Need to Know
Key Takeaways
Kodiak Sciences’ (KOD - Free Report) shares have surged 24% over the past three months, driven by strong momentum around its late-stage pipeline and improving financial position, which have boosted investor confidence.
The company’s lead programs—tarcocimab, KSI-501 and especially KSI-101—are in late-stage development for common and serious retinal indications such as diabetic retinopathy (DR), wet age-related macular degeneration (wet AMD) and macular edema.
Over the past year, shares of Kodiak have surged 290.5% compared with the industry’s 34.9% growth.
Image Source: Zacks Investment Research
Kodiak’s Strong Pipeline a Catalyst
Investor sentiment has been bolstered by clear visibility on multiple late-stage catalysts. Building on the success of the GLOW1 study, Kodiak is evaluating the efficacy and safety of tarcocimab in treatment-naïve patients with DR in the phase III GLOW2 study, with top-line data expected in the first quarter of 2026.
KOD’s second clinical candidate, KSI-501, a dual inhibitor Trap-Antibody-Fusion bioconjugate molecule, is designed to target concurrent inflammation and abnormal angiogenesis observed in the pathogenesis of retinal vascular diseases.
The company is also studying tarcocimab as a second investigational arm in the phase III DAYBREAK study for the treatment of patients with wet AMD, with KSI-501 being the first investigational arm. Top-line data from both arms of the DAYBREAK study are anticipated in the third quarter of 2026.
Success in these pivotal programs could enable a single regulatory filing for tarcocimab across three major retinal indications, representing a significant commercial opportunity.
Kodiak has advanced KSI-101, its third clinical candidate, into two pivotal phase III studies (PEAK and PINNACLE) for the treatment of patients with macular edema secondary to inflammation (MESI). Both studies are currently enrolling patients with top-line results expected in late 2026 and early 2027, respectively.
Additionally, Kodiak is evaluating KSI-101 in the same patient population under an early-stage APEX study. In November, the follow-up data from the study demonstrated meaningful visual improvements and retinal drying, validating its dual IL-6 and VEGF mechanism. Final data from the study is expected to be released shortly.
Although Kodiak remains a clinical-stage biotech with no approved products, the steady progress of its potential pipeline candidates reinforced investor confidence, which underpinned the stock’s recent run.
Robust Funding
Kodiak Sciences completed a successful equity offering of 8.0 million shares in December 2025, which strengthened its balance sheet and extended the company’s cash runway to support operations and pipeline development.
Kodiak Sciences Inc. Price
Kodiak Sciences Inc. price | Kodiak Sciences Inc. Quote
Kodiak Sciences’ Zacks Rank & Stocks to Consider
KOD currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the biotech sector are Assertio Holdings (ASRT - Free Report) , Alkermes (ALKS - Free Report) and Castle Biosciences (CSTL - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Assertio’s 2026 loss per share have narrowed from 30 cents to 28 cents. ASRT shares have declined 2% over the past year.
Assertio’s earnings beat estimates in one quarter and missed in the remaining three quarters, with the average negative surprise being 35.21%.
Over the past 60 days, estimates for Alkermes’ 2026 earnings per share have increased from $1.54 to $1.91. ALKS shares have risen 6.3% over the past year.
Alkermes’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average earnings surprise being 4.58%.
Over the past 60 days, estimates for Castle Biosciences’ 2026 loss per share have narrowed from $1.06 to 96 cents. CSTL shares have risen 17.3% over the past year.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 66.11%.